Synthesis and antihyperglycemic evaluation of various protoberberine derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 5, 2006, Pages 1380-1383

  Bian, Xiaoli ^a   He, Langchong ^a   Yang, Guangde ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cell membrane chromatography; Hypoglycemic effect; Protoberberine derivatives

Indexed keywords

BERBERINE; HYPERGLYCEMIC AGENT; LIGAND; PROTOBERBERINE DERIVATIVE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HYPERGLYCEMIA; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ALLOXAN; ANIMALS; BERBERINE ALKALOIDS; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; MICE; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 31344458055     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.11.045     Document Type: Article

References (26)

1. R.A. DeFronzo, R.C. Bonadonna, and E. Ferrannini Diabetes Care 15 1992 318
2. S.E. Kahn, and D.J. Porte Diabetes Mellitus 45 1996 487
3. N.B. Ruderman, and S.H. Schneider Diabetes Care 15 1992 1784
4. M. Satyanarayana, T. Priti, and K. Brajendra Bioorg. Med. Chem. 12 2004 883
5. P.H. Bennett Diabet. Metab. Rev. 13 1997 583
6. W.K. Ward, J.C. Beard, J.B. Halter, M.A. Pfeifer, and D.J.R. Porte Jr. Diabetes Care 7 1984 491
7. C.J. Bailey Proc. Nutr. Soc. 50 1991 619
8. E. Steven, and M.B. Kahn Am. J. Med. 108 2000 2s
9. F.M. Gribble, and F.M. Ashcroft Metab. Clin. Exp. 49 2000 3
10. J.P. Andrew, T. Claire, and M. Craig Mckay Bioorg. Med. Chem. Lett. 14 2004 813
11. F.M. Ashcroft, and F.M. Gribble Diabetes 42 1999 903
12. F.M. Gribble, and S.J. Tucker Diabetes 47 1998 1412
13. M.V. Mikhailov, and E.A. Mikhailov FEBS Lett. 482 2000 59
14. M.V. Mikhailov, and S.J.H. Ashcroft J. Biol. Chem. 275 2000 3360
15. H. Langchong, and G. Xindu New Progr. Biomed. Chromatogr. 3 1996 8
16. H. Langchong, Y. Guangde, and G. Xindu Chin. Sci. Bull. 44 1999 826
17. H. Langchong, W. Sicen, and X. Geng Chromatographia 54 2001 77
18. Y. Guangde, H. Langchong, and B. Xiaoli Chin. Sci. Bull. 50 2005 1709
19. D. Liu, L.X. Yang, and S.-L. Cui China J. Chin. Mater. Med. 22 1997 79
20. K. Iwasa, K. Hye-Sook, and W. Yusuke Eur. J. Med. Chem. 33 1998 65
21. Z. Jie, and W. Liqin Chinese J. Intergrative Med. Cardio/Cerebrovasc. Dis. 1 2003 160
22. K. Iwasa, H. Nanba, and D.-U. Lee Planta Med. 64 1998 748
23. K. Iwasa, M. Kam imauchi, and M. Ueki Eur. J. Med. Chem. 31 1996 469
24. K. Iwasa, and M. Kam imauchi Planta Med. 63 1997 196
25. Shuyun, X.; Rulian B.; Xiu C. In Method of Pharmacological Experiment. The People's Medical Publishing House, Beijing, 2002; pp 1037.
26. Note: the chromatographic conditions in the CMC model: rabbit pancreatic-islet β-cell membrane column (50 mm × 2.0 mm i.d.) was used. The mobile phase was 25 mM ammonium sulfate buffer (pH 7.4), with a flow rate of 0.5 mL/min. The detection wavelength was 262 nm, at a column temperature of 37 ± 0.5°C.